Inflammation Markers Among Schizophrenia Patients Who Use Cannabis.

IF 0.8 4区医学 Q4 CLINICAL NEUROLOGY

Clinical Neuropharmacology Pub Date : 2023-06-20 DOI:10.1097/WNF.0000000000000558

Jonathan Fridman, Esther Bloemhof-Bris, Shira Weizman, Tal Kessler, Dorit Porat, Amos Ivry, Aviva Wolf, Rafael Stryjer, Assaf Shelef

{"title":"Inflammation Markers Among Schizophrenia Patients Who Use Cannabis.","authors":"Jonathan Fridman, Esther Bloemhof-Bris, Shira Weizman, Tal Kessler, Dorit Porat, Amos Ivry, Aviva Wolf, Rafael Stryjer, Assaf Shelef","doi":"10.1097/WNF.0000000000000558","DOIUrl":null,"url":null,"abstract":"Objectives: The mechanism of inflammation of the immune system, for example, such circulatory markers as the neutrophil-to-lymphocyte ratio (NLR) and mean platelet volume (MPV), has been shown in many studies to be associated with schizophrenia. In addition, it has been shown that the cannabidiol component reduces the activation of the acquired immune system. This study examined the differences in the levels of NLR and MPV among schizophrenia patients with cannabis use versus those without.Methods: In 2019 to 2020, a retrospective cross-sectional study was conducted based on digital medical records. Demographic, clinical, and complete blood cell count data were collected from records of rehospitalization of active psychotic schizophrenia inpatients. Data on NLR, MPV values, and demographic and clinical characteristics were compared between the groups and according to the degree of prevalence of cannabis use.Results: No differences were found in the NLR and MPV values between the groups.Conclusion: The results were contrary to our expectations. These results may be explained by the presentation of a \"pseudo-balanced\" picture created when multiple processes affect inflammatory indices.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2023-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000558","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The mechanism of inflammation of the immune system, for example, such circulatory markers as the neutrophil-to-lymphocyte ratio (NLR) and mean platelet volume (MPV), has been shown in many studies to be associated with schizophrenia. In addition, it has been shown that the cannabidiol component reduces the activation of the acquired immune system. This study examined the differences in the levels of NLR and MPV among schizophrenia patients with cannabis use versus those without.

Methods: In 2019 to 2020, a retrospective cross-sectional study was conducted based on digital medical records. Demographic, clinical, and complete blood cell count data were collected from records of rehospitalization of active psychotic schizophrenia inpatients. Data on NLR, MPV values, and demographic and clinical characteristics were compared between the groups and according to the degree of prevalence of cannabis use.

Results: No differences were found in the NLR and MPV values between the groups.

Conclusion: The results were contrary to our expectations. These results may be explained by the presentation of a "pseudo-balanced" picture created when multiple processes affect inflammatory indices.

查看原文本刊更多论文

使用大麻的精神分裂症患者的炎症标志物

目的:免疫系统炎症的机制，例如，循环标志物如中性粒细胞与淋巴细胞比率(NLR)和平均血小板体积(MPV)，已在许多研究中显示与精神分裂症有关。此外，已经证明大麻二酚成分降低了获得性免疫系统的激活。本研究检测了使用大麻的精神分裂症患者与未使用大麻的精神分裂症患者NLR和MPV水平的差异。方法:2019 - 2020年，基于数字病案进行回顾性横断面研究。人口统计学、临床和全血细胞计数数据收集自活动性精神分裂症住院患者的再住院记录。NLR、MPV值、人口学和临床特征数据在两组之间进行比较，并根据大麻使用的流行程度进行比较。结果:两组间NLR、MPV值无明显差异。结论:结果与我们的预期相反。这些结果可以解释为当多个过程影响炎症指数时产生的“伪平衡”图像。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Neuropharmacology 医学-临床神经学

CiteScore

1.20

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.